---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017028"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:44:09.819368+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics reports Q3 2022 financials; FDA clears interim analysis for uproleselan Phase 3

## Summary
- Cash $51.6M as of Sep 30, 2022 vs $90.3M at Dec 31, 2021; cash runway extended to end of 2023.
- FDA cleared protocol amendment for interim utility analysis of uproleselan Phase 3 in relapsed/refractory AML.
- Blinded pooled survival data show patients living longer than historically expected; DMC meeting by end Q1 2023.
- Final survival events trigger projected around year-end 2023, later than originally anticipated.
- R&D expenses decreased to $4.9M from $13.3M YoY due to Phase 3 enrollment completion.

## SEC filing metadata
- accession: 0001558370-22-017028
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/0001558370-22-017028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/glyc-20221109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017028
- JSON: https://secwatch.observer/filing/0001558370-22-017028.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017028.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported third quarter ended September 30, 2022 results: revenue There was no revenue recognized during the three months ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Revenue: There was no revenue recognized during the three months ended September 30, 2022
  - Result: reported results
  source text: On November 9, 2022, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/0001558370-22-017028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.